论文部分内容阅读
目的观察复方阿嗪米特(泌特)联合加味玉屏风散(童康片)治疗反复呼吸道感染儿(复感儿)消化不良的临床疗效、安全性和依从性。方法复感儿消化不良者156例随机分成观察组及对照组,每组各78例,观察组和对照组均给予童康片口服,疗程4周;观察组同时给予泌特口服,疗程4周。治疗前和治疗后每周分别评价患儿消化不良的总症状积分与单项症状积分,同时观察药物不良反应和患儿的依从情况。结果治疗1、2、3、4周后消化不良总症状积分观察组(8.7±1.6)分(、5.8±1.3)分、(3.6±0.8)分、(1.5±0.6)分,对照组(11.6±2.1)分、(8.7±1.6)分、(7.2±1.4)分(、6.4±1.1)分,观察组改善明显优于对照组,差异有统计学意义(P<0.01或<0.05)。治疗4周后,患儿消化不良的主要症状,依次为厌食、早饱、上腹痛、腹胀、恶心、呕吐的单项症状有效改善率,观察组明显高于对照组98.7%vs 71.4%9、6.9%vs 69.1%、94.1%vs 67.7%、98.6%vs 72.4%、92.4%vs 71.2%、94.0%vs 67.2%(均P<0.01);总有效率观察组显著高于对照组(97.4%vs 70.5%,P<0.01)。未发现药物不良反应。结论泌特联合童康片治疗复感儿消化不良可显著改善消化不良的总症状积分及单项症状积分,临床疗效显著,患儿依从性和安全性好,无不良反应,值得临床推广应用。
Objective To observe the clinical efficacy, safety and compliance of compound Azimit (Triticum) combined with Modified Yupingfeng San (Tongkang Pian) in treating children with recurrent respiratory tract infection (FCH) dyspepsia. Methods 156 cases of recurrent children with dyspepsia were randomly divided into observation group and control group, 78 cases in each group. The observation group and the control group were given Tongkang tablets orally, the course of treatment for 4 weeks; the observation group were given oral administration of special, 4 weeks . Pre-treatment and post-treatment were evaluated weekly for children with dyspepsia symptom score and individual symptom scores, while observing adverse drug reactions and children’s compliance. Results The total dyspeptic symptom scores in the observation group (8.7 ± 1.6), (5.8 ± 1.3) points, (3.6 ± 0.8) points, (1.5 ± 0.6) points in the observation group, 11.6 ± 2.1) points, (8.7 ± 1.6) points and (7.2 ± 1.4) points (6.4 ± 1.1) points respectively. The observation group improved significantly better than the control group, the difference was statistically significant (P <0.01 or <0.05). After 4 weeks of treatment, the main symptoms of dyspepsia in children were as follows: anorexia, early satiety, upper abdominal pain, bloating, nausea and vomiting, single symptom effective improvement rate was significantly higher in the observation group than in the control group 98.7% vs 71.4% 9,6.9 % vs 69.1%, 94.1% vs 67.7%, 98.6% vs 72.4%, 92.4% vs 71.2%, 94.0% vs 67.2% (all P <0.01); the total effective rate in the observation group was significantly higher than that in the control group (97.4% vs 70.5% %, P <0.01). No adverse drug reaction was found. Conclusion Combined with Tongkang Tablet Treating Infantile dyspepsia can significantly improve the indigestion of the total symptom scores and individual symptom scores, clinical efficacy was significant, children with good compliance and safety, no adverse reactions, it is worthy of clinical application.